Provided by Tiger Trade Technology Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

72.18
-0.6300-0.87%
Volume:216.58K
Turnover:15.67M
Market Cap:3.17B
PE:-66.68
High:74.00
Open:72.55
Low:71.78
Close:72.81
52wk High:85.25
52wk Low:48.20
Shares:43.88M
Float Shares:32.68M
Volume Ratio:0.56
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0824
EPS(LYR):-1.5900
ROE:-13.68%
ROA:-5.48%
PB:9.14
PE(LYR):-45.40

Loading ...

Tarsus Pharmaceuticals Inc - Eligible for Additional Milestones and Tiered Royalties for Tp-03 in Greater China

THOMSON REUTERS
·
Mar 23

Tp-03 (Lotilaner Ophthalmic Solution) 0.25% NOW Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

THOMSON REUTERS
·
Mar 23

Grand Pharmaceutical says China NMPA approves TP-03 for Demodex blepharitis commercialization

Reuters
·
Mar 22

LifeSci Capital Remains a Buy on Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Mar 21

Tarsus Pharmaceuticals Director William J. Link disposed of USD 861,757 of common shares

Reuters
·
Mar 19

Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS) and Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Mar 17

Tarsus Pharmaceuticals Bets Big on XDEMVY Growth

TIPRANKS
·
Mar 10

Tarsus COO Neervannan Seshadri Disposes of Common Shares

Reuters
·
Mar 06

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Feb 27

Tarsus Pharmaceuticals (TARS) Is Up 14.8% After XDEMVY-Fueled Revenue Surge and New Equity Shelf Filing

Simply Wall St.
·
Feb 26

Tarsus Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Feb 25

Tarsus Pharmaceuticals : Oppenheimer Raises Target Price to $105 From $95

THOMSON REUTERS
·
Feb 25

Barclays Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Feb 25

Tarsus Pharmaceuticals rises 11.6%

TIPRANKS
·
Feb 24

Stock Track | Tarsus Pharmaceuticals Soars 10.64% Intraday on Positive Analyst Ratings and Price Target Increases

Stock Track
·
Feb 24

Tarsus Pharmaceuticals price target raised to $90 from $88 at BofA

TIPRANKS
·
Feb 24

Stock Track | Tarsus Pharmaceuticals Soars 6.44% Pre-Market on Positive Analyst Outlook and Growth Prospects

Stock Track
·
Feb 24

Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline

TIPRANKS
·
Feb 24

Stock Track | Tarsus Pharmaceuticals Soars 6.15% After-Hours on Strong Q4 Revenue Beat and XDEMVY Sales Growth

Stock Track
·
Feb 24

Earnings Flash (TARS) Tarsus Pharmaceuticals Posts Q4 Loss $0.20, vs. Loss of $0.60 a Year Ago

MT Newswires Live
·
Feb 24